DOCSLIB.ORG

Nutritional Aspects of Inborn Errors of Metabolism

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nutritional Aspects of Inborn Errors of Metabolism Feeding the Sick Infant, edited by Léo Stem. Nestlé Nutrition Workshop Séries, Vol. 11. Nestec Ltd, Vevey/Raven Press, New York © 1987. Nutritional Aspects of Inborn Errors of Metabolism Michel Vidailhet Department of Pediatrics 3, Hôpital d'Enfants, 54511 Vandoeuvre-lès-Nancy, France GENERALITIES Introduction Inherited metabolic disorders in volve différent nutritional aspects. On the one hand, the disease itself can impair normal nutrition. During the end of the fetal growth period and the first two years of life, the human brain grows at an impres- sive rate. This brain growth spurt period (1) is associated with a very high rate of protein synthesis that makes the central nervous system vulnérable to any interfér­ ence with protein synthesis. Biochemical insuit at this critical period may hâve a permanent effect on brain function. The accumulation of one or more substrates above an enzymatic block can af- fect normal metabolism and nutrition. For example, in amino acid disorders the high tissue levels of accumulated amino acid may competitively inhibit the trans­ port of other amino acids sharing the same transport mechanism. Amino acids in excess may interfère with the activity of enzymes involved in the metabolism of other amino acids. Short-chain fatty acids, oxo-acids, and other organic acids in- teract with ureogenesis, gluconeogenesis, pyruvate metabolism, etc. In fructose in­ tolérance, the accumulation of fructose-1-phosphate causes the trapping of inor- ganic phosphate. The fall in cellular ATP and ADP inhibits several enzymatic activities and results in altérations of energy metabolism. On the other hand, the metabolic block can induce severe deficiencies in one or more metabolites normally produced by the pathway. In ail urea cycle disorders, except arginase deficiency, arginine becomes essential; without arginine supple- mentation, stunted growth and hyperammonemia occur despite protein restriction. Undemutrition may be the conséquence of gênerai metabolic disturbances. Chrome hypoglycemia, lactic acidosis, and secondary hypercorticism explain the poor growth observed in glycogenosis type I. Severe and progressive impairments of liver function and, to a lesser degree, of rénal tubular function play a major rôle in the development of malnutrition, which appears in galactosemia, fructose intolérance, or in hereditary tyrosinosis. 205 206 INBORN ERRORS OF METABOUSM Even in lysosomal disorders, stunted growth can begin in the first few weeks of life, as in Wolman disease, probably because of the importance of the liver and small bowel lésions in this disease. In transport mechanism disorders, levels of spécifie nutrients may be decreased, with, as a conséquence, symptoms of deficiency, as in acrodermatitis enteropath- ica secondary to zinc malabsorption. On the other hand, surprisingly enough, cystinuria-lysinuria does not resuit in lysine or arginine deficiency, despite the increased rénal excrétion and the intesti­ nal malabsorption of thèse amino acids. Such an apparent contradiction is now well explained by the importance of direct intestinal absorption of di- and tripeptides. Dietetic Treatment Because of the multiplicity of inborn errors of metabolism, it is not possible to review ail their nutritional drawbacks. Some metabolic disorders are harmless variations of normal metabolism (e.g., essential fructosuria, cystathioninuria), whereas others cause severe illness or mental détérioration early in life. The latter are often treatable by means of spécial diets and their nutritional aspects appear most important for clinical practice. A block in galactose, fructose, or amino acid metabolism leads to accumulation of thèse substrates and their metabolites, which can be prevented by spécifie restricted diets. Such diets may hâve to be continued for many years, sometimes indefinitely, as in maple syrup urine disease (MSUD), urea cycle disorders, galactosemia, etc. The prolonged use of a synthetic or semisynthetic diet may hâve adverse effects if the absolute and relative amounts of the différent nutrients are not well provided. Thèse diets must provide: (a) adéquate calorie intake; (b) minimum requirements of essential amino acids and nitrogen; (c) vitamins, minerais, and trace éléments in sufficient amounts; (d) normal products of the metabolic pathway that can no longer be produced and that hâve essential functions (e.g., tyrosine in phenylketo- nuria (PKU), arginine in urea cycle disorders, cysteine in homocystinuria, free glucose in glucose-6-phosphatase deficiency). The biodisposability and intestinal absorption of several nutrients, such as vitamins or trace éléments, may be very différent between synthetic diets and normal foodstuffs. Apart from the main ef­ fects intended by the treatment, it is important to be concerned about ail nutritional problems that may resuit from the disease and its dietetic therapy. According to the type of metabolic disorder one can distinguish several kinds of dietetic manipulations. Supplementation This is the easiest to perform. An example is zinc supplementation for acroder­ matitis enteropathica. In Menkes disease parenteral supplementation with copper gives much less satisfactory results. A particular group of inherited metabolic diseases is the group of vitamin- INBORN ERRORS OF METABOUSM 207 dépendent disorders. Several amino acidemias and organic acidemias are com- pletely or partially cured by large doses of vitamins that are the precursors of spé­ cifie cofactors involved in defective enzymatic reactions. Table 1 lists thèse dis- eases. According to the kind of enzymatic deficiency, a metabolic disorder, as methylmalonic acidemia, may be fully or partially responsive or unresponsive to B12 vitamin therapy. In every instance it is important to try such cofactor therapy, which is easier to apply than restricted diets. Exclusion Such diets can be proposed when the nutrient to be excluded is not an essential one. This is the case for galactose (galactosemia, galactokinase deficiency, glyco- genosis type I) and for fructose (fructose intolérance, fructose-1, 6-diphosphatase deficiency, glycogenosis type I). Restriction In disorders involving an essential amino acid, the diet must supply the minimal requirement for this amino acid that is restricted relative to the total protein intake. Most of the natural protein is replaced by a protein substitute deprived of this amino acid (Tables 2 and 3). TABLE 1. Amino acid and organic acid disorders that may be responsive to vitamin therapy Disease Vitamin Dose Homocystinuria (cystathionine synthetase deficiency) Cystathioninuria Pyridoxine 100-150 mg/day Hyperoxaluria Xanthurenic aciduria Methylmalonic acidemia (MMA) (mutase deficiency) B 0.25-1 mg/day Homocystinuria + MMA + hypomethioninemia 12 Homocystinuria + hypomethioninemia Folie acid 10-50 mg/day Maple syrup urine disease Lactic acidosis (pyruvate dehydrogenâte [PDH] Thiamin 10-20 mg/day deficiency) Dicarboxylic aciduria Riboflavin 100 mg/day Type 2 glutaric aciduria Hartnup disease Niacin 50-200 mg/day Hyperphenylalaninemia with dihydropterin synthetase BH„* 3-5 mg/kg deficiency Tyrosinemia C 50-100 mg/day Multiple carboxylase deficiency (3-methylcrotonylglycine, Biotin 10 mg/day propionic, lactic acids) "Cofactor φ + + + ο ο + + c 1 ε + +-Q.+ + +00 + + ! (0 Ο) Φ Ο ΟΟ ΝΜΙΟΟΟΟΙΟ in r» ΙΟΜΧΟΟΙΟΜ S ° *ί C0 C0 CM 0J τ!· -«t CO F5 ! <ο •S οο Ο υ Φ .C C •S φ S •c (Ο τ- Q. II h- m 00SSOOO01 ο ΙΟ ΙΟ ϋ φ ι§ ο ο ο ο ο ο ο 8 s: σ> Φ Ι 5 ç σ> "5 Φ ο Ρ° ιη ο Ο Ο Ο Ο Ο Ο CD ω trooooonio «0 Φ < τ- m Φ â .»"§ î?s c °> II Ο) fc i- (β ο ^ C φ Φ Ο Ο Ο Ο Ο Ο Ο Ο Ο Φ Ε 1° 00 τ- CM UJOOÇ •ses. IE f Ρ α. flffilîîîj CM § 1 Sx Τ3 3 φ ?Ζ, ε α. ζ _J < 1 û. D. < CL Σ 1 1NBORN ERRORS OF METABOUSM 209 TABLE 3. Low amino acid and galactose-free substitutes Disorder Substrate lowered Name of Product Cystinosis cystine (0.5 g/100 g) Albumaid X Cysf Maple syrup urine disease Branched-chain amino M.S.U.D. Aid· acids Leucidonfc M.S.U.D. 1 and 2e Homocystinuria (classical Methionine Albumaid X Meth* form) Methionaid" Hom 1 and 2e Tyrosinosis Phenylalanine and tyrosine Albumaid X Tyr* Tyrosinaid* Tyrosidon" Tyr 1 and 2e Histidinemia Histidine Histinaid* Histidon" Hist 1 and 2e Hyperlysinemia Lysine Lys 1 and 2e Urea cycle disorders Nonessential amino acids Essential Amino Acid Mixture* U.C.D. 1 and 2e Nitrogen Ketosteril" Propionic and Isoleucine, methionine, OS 1 and 2e Methylmalonic acidemias threonine, valine Galactosemia Galactose Galactomin 19* Nutramigen" Pregestimil· Isomil' Prosobee" Vegelact9 •Scientific Hospital Supplies (England) •"Nutricia (The Netherlands) cMilupa (Fédéral Republic of Germany) ''Fresenius (Fédéral Republic of Germany) "Mead-Johnson (United States) 'Ross (United States) «Gallia (France) For PKU, see Table 2. A major danger of such diets is the occurrence of nutritional deficiencies, partic- ularly a deficiency in the restricted amino acid. Phenylalanine deficiency owing to overtreatment of PKU has been well described. The baby fails to gain weight; de- velops a severe, red, cutaneous rash starting in the napkin région; vomits; becomes anorexie and léthargie; and may develop alopecia, edema, and fréquent infections. Death or définitive mental retardation may ensue. Deficiency of other essential amino acids has the same gênerai effect. In several diseases such as MSUD, propionic acidemia (PA), B12 unresponsive methylmalonic acidemia (MMA), and infantile tyrosinosis, the borderline between deficiency and excess is narrow, and monitoring is more difficult than in PKU. Low protein diets, in which total protein is restricted and replaced by nonprotein calories, are necessary in several diseases such as urea cycle disorders. They give 210 INBORN ERRORS OF METABOUSM way to protein lack and sometimes necessitate the use of an essential amino acid mixture or of keto- and hydroxy-analogues of essential amino acids. Emergency Conditions Some of the diseases manifest themselves in severe acute forms, particularly in the neonatal period. This is the case for several amino acid disorders like MSUD, urea cycle disorders, MMA, PA, and isovaleric acidemia (IVA). Certain clinical findings are suggestive of a hereditary metabolic disease that frequently mimics neonatal sepsis.
Load more

Recommended publications
  • Cystinosis, Has Been Reported Previomly in 3 Patients Using (1
    , PKU GENE - WSSIBLE CAUSE OF NON-SPECIFIC UENTAL RE- RARE PHENOTYPES OF PLACENTAL ALKALINE PHOSPHATASE: AN 523 TARDATION. Atsuko Fujimoto and Samuel P. Bes-n, ANALYSIS OF RELATIONSHIPS WITH SOME NEONATAL AND b USC Hed. Sch., Dept. Pediatrics, Los Angeles MATERNAL VARIABLES. F. Gloria-Bottini, A. Polzonetti, The Justification Hypothesis (J. Ped. 81:834, 1972) proposes . Bentivoglia, P. Lucarelli and E. Bottini (Spon. by C.D. Cook). that deficiencies in non-essential amino acids might cause mental Jniv. of Camerino, Dept. of Genetics and Computer Center and retardation. The mother heterozygous for synthesis of any one of Jniv. of Rome, Dept. of Pediatrics. the non-essential amino acids would deprive her fetus partially The large number (>15) and frequency (-2%) of rare placental and the heterozygous or homozygous fetus would be more or less alkaline phosphatase (PI) alleles represent a very special case unable to make up for the deficiency. Berman and Ford (Lancet i: among polymorphic enzymes. Since the PI gene is active only dur- 767, 1977) showed that such concatenation of heterozygous mother ing intrauterine life, the allelic diversity and its maintenance and heterozygous fetus is associated with significantly lower IQ. nay be connected with intrauterine environment and with fetal Our own wark has verified this finding. The possibility that development. 1700 newborn infants ( 1271 Caucasians, 337 Negroes heterozygosity for PKU in mother and fetus might be a cause of a and 92 Puerto Ricans), collected at Yale-New Haven Hospital from 1arq.e amount of "non-specific" mental retardation was tested by 1968-1971, were studied. An analysis of the relationship between looking for associated heterozygosity for PKU in mother and child rare PI phenotype and the following 14variableswas carried out: among.12 families in a genetic clinic.
    [Show full text]
  • Effect of Propionic Acid on Fatty Acid Oxidation and U Reagenesis
    Pediat. Res. 10: 683- 686 (1976) Fatty degeneration propionic acid hyperammonemia propionic acidemia liver ureagenesls Effect of Propionic Acid on Fatty Acid Oxidation and U reagenesis ALLEN M. GLASGOW(23) AND H. PET ER C HASE UniversilY of Colorado Medical Celller, B. F. SlOlillsky LaboralOries , Denver, Colorado, USA Extract phosphate-buffered salin e, harvested with a brief treatment wi th tryps in- EDTA, washed twice with ph os ph ate-buffered saline, and Propionic acid significantly inhibited "CO z production from then suspended in ph os ph ate-buffe red saline (145 m M N a, 4.15 [I-"ejpalmitate at a concentration of 10 11 M in control fibroblasts m M K, 140 m M c/, 9.36 m M PO" pH 7.4) . I n mos t cases the cells and 100 11M in methyl malonic fibroblasts. This inhibition was we re incubated in 3 ml phosph ate-bu ffered sa lin e cont aining 0.5 similar to that produced by 4-pentenoic acid. Methylmalonic acid I1Ci ll-I4Cj palm it ate (19), final concentration approximately 3 11M also inhibited ' 'C0 2 production from [V 'ejpalmitate, but only at a added in 10 II I hexane. Increasing the amount of hexane to 100 II I concentration of I mM in control cells and 5 mM in methyl malonic did not impair palmit ate ox id ation. In two experiments (Fig. 3) the cells. fibroblasts were in cub ated in 3 ml calcium-free Krebs-Ringer Propionic acid (5 mM) also inhibited ureagenesis in rat liver phosphate buffer (2) co nt ain in g 5 g/ 100 ml essent iall y fatty ac id slices when ammonia was the substrate but not with aspartate and free bovine se rum albumin (20), I mM pa lm itate, and the same citrulline as substrates.
    [Show full text]
  • Oxalate Loading Test: a Screening Test for Steatorrhoea
    Gut: first published as 10.1136/gut.20.12.1089 on 1 December 1979. Downloaded from Gut, 1979, 20, 1089-1094 Oxalate loading test: a screening test for steatorrhoea D. S. RAMPTON', G. P. KASIDAS, G. ALAN ROSE, AND MARTIN SARNER2 From University College Hospital, London, St. Peter's Hospitals and Institute of Urology, London SUMMARY To investigate the possibility of measuring urinary oxalate output instead of faecal fat excretion as an outpatient screening test for steatorrhoea, we determined 24 hour urinary oxalate and five day faecal fat excretion before and during an oral load of sodium oxalate 600 mg daily (oxalate 4-44 mmol), in 32 patients with suspected malabsorption on a diet containing oxalate 30 mg (0-33 mmol), fat 50 g (180 mmol), and calcium 1 g (25 mmol). Nineteen patients proved to have steatorrhoea (mean faecal fat 62 mmol/24 h, range 19-186 mmol) of varying aetiologies. On the diet alone, urinary oxalate was raised in only nine of these patients (mean 0 25 mmol/24 h, range 0-08-059 mmol) (normal <0 20). By contrast, when the diet was supplemented with oral sodium oxalate, all 19 patients with steatorrhoea had hyperoxaluria (mean 0-91 mmol/24 h, range 046- 1P44 mmol) (normal <0-44). There was a significant positive linear relationship between urinary oxalate and faecal fat when the 32 patients were on the high oxalate intake (r=0*73, P <0.001), but not when they were on the low oxalate intake. Mean percentage absorption of orally administered oxalate was 58+09% (±1 SD) in normal subjects and 14-7+6-0% (P <0.002) in patients with steatorrhoea.
    [Show full text]
  • Incidence of Inborn Errors of Metabolism by Expanded Newborn
    Original Article Journal of Inborn Errors of Metabolism & Screening 2016, Volume 4: 1–8 Incidence of Inborn Errors of Metabolism ª The Author(s) 2016 DOI: 10.1177/2326409816669027 by Expanded Newborn Screening iem.sagepub.com in a Mexican Hospital Consuelo Cantu´-Reyna, MD1,2, Luis Manuel Zepeda, MD1,2, Rene´ Montemayor, MD3, Santiago Benavides, MD3, Hector´ Javier Gonza´lez, MD3, Mercedes Va´zquez-Cantu´,BS1,4, and Hector´ Cruz-Camino, BS1,5 Abstract Newborn screening for the detection of inborn errors of metabolism (IEM), endocrinopathies, hemoglobinopathies, and other disorders is a public health initiative aimed at identifying specific diseases in a timely manner. Mexico initiated newborn screening in 1973, but the national incidence of this group of diseases is unknown or uncertain due to the lack of large sample sizes of expanded newborn screening (ENS) programs and lack of related publications. The incidence of a specific group of IEM, endocrinopathies, hemoglobinopathies, and other disorders in newborns was obtained from a Mexican hospital. These newborns were part of a comprehensive ENS program at Ginequito (a private hospital in Mexico), from January 2012 to August 2014. The retrospective study included the examination of 10 000 newborns’ results obtained from the ENS program (comprising the possible detection of more than 50 screened disorders). The findings were the following: 34 newborns were confirmed with an IEM, endocrinopathies, hemoglobinopathies, or other disorders and 68 were identified as carriers. Consequently, the estimated global incidence for those disorders was 3.4 in 1000 newborns; and the carrier prevalence was 6.8 in 1000. Moreover, a 0.04% false-positive rate was unveiled as soon as diagnostic testing revealed negative results.
    [Show full text]
  • Inherited Metabolic Disease
    Inherited metabolic disease Dr Neil W Hopper SRH Areas for discussion • Introduction to IEMs • Presentation • Initial treatment and investigation of IEMs • Hypoglycaemia • Hyperammonaemia • Other presentations • Management of intercurrent illness • Chronic management Inherited Metabolic Diseases • Result from a block to an essential pathway in the body's metabolism. • Huge number of conditions • All rare – very rare (except for one – 1:500) • Presentation can be non-specific so index of suspicion important • Mostly AR inheritance – ask about consanguinity Incidence (W. Midlands) • Amino acid disorders (excluding phenylketonuria) — 18.7 per 100,000 • Phenylketonuria — 8.1 per 100,000 • Organic acidemias — 12.6 per 100,000 • Urea cycle diseases — 4.5 per 100,000 • Glycogen storage diseases — 6.8 per 100,000 • Lysosomal storage diseases — 19.3 per 100,000 • Peroxisomal disorders — 7.4 per 100,000 • Mitochondrial diseases — 20.3 per 100,000 Pathophysiological classification • Disorders that result in toxic accumulation – Disorders of protein metabolism (eg, amino acidopathies, organic acidopathies, urea cycle defects) – Disorders of carbohydrate intolerance – Lysosomal storage disorders • Disorders of energy production, utilization – Fatty acid oxidation defects – Disorders of carbohydrate utilization, production (ie, glycogen storage disorders, disorders of gluconeogenesis and glycogenolysis) – Mitochondrial disorders – Peroxisomal disorders IMD presentations • ? IMD presentations • Screening – MCAD, PKU • Progressive unexplained neonatal
    [Show full text]
  • Blueprint Genetics Primary Hyperoxaluria Panel
    Primary Hyperoxaluria Panel Test code: KI0801 Is a 3 gene panel that includes assessment of non-coding variants. Is ideal for patients with a clinical suspicion of hyperoxaluria. About Primary Hyperoxaluria The primary hyperoxalurias are rare disorders of glyoxylate metabolism, which result in markedly increased endogenous oxalate synthesis by the liver. They are characterized by an excess of oxalate resulting in manifestations ranging from occasional renal stones, recurrent nephrolithiasis and nephrocalcinosis to end-stage renal disease (ESRD) and systemic oxalosis. Presenting ranges from the neonatal period to adulthood. Among disorders causing hyperoxaluria, the primary hyperoxalurias are the most severe, ultimately leading to ESRD and if untreated, death in most patients. Type I primary hyperoxaluria (PH1), is caused by deficient or absent activity of liver-specific peroxisomal alanine glyoxylate aminotransferase (AGT). In some patients with PH1 type disease, the enzyme is present but mistargeted to mitochondria where it is metabolically inactive. The severe infantile form is characterized by a failure to thrive, nephrocalcinosis with or without nephrolithiasis and early ESRD. Onset in childhood and adolescence is often characterized by recurrent urolithiasis (with or without nephrocalcinosis) and progressive renal failure. The late onset form is characterized by occasional renal stones with onset in adulthood, but acute renal failure caused by bilateral obstruction of the kidneys by oxalate stones may occur. Other manifestations include urinary tract infections, dysuria and hematuria. The ongoing systemic oxalosis also may lead to other clinical manifestations such as cardiac conduction defects, vascular calcification with distal gangrene, disturbed vision, specific brown colored retinal deposits, skin nodules, joint involvement and bone disease leading to fractures in long-term dialysis-dependent patients.
    [Show full text]
  • Redalyc.The Nutritional Limitations of Plant-Based Beverages in Infancy
    Nutrición Hospitalaria ISSN: 0212-1611 [email protected] Sociedad Española de Nutrición Parenteral y Enteral España Vitoria, Isidro The nutritional limitations of plant-based beverages in infancy and childhood Nutrición Hospitalaria, vol. 34, núm. 5, 2017, pp. 1205-1214 Sociedad Española de Nutrición Parenteral y Enteral Madrid, España Available in: http://www.redalyc.org/articulo.oa?id=309253341026 How to cite Complete issue Scientific Information System More information about this article Network of Scientific Journals from Latin America, the Caribbean, Spain and Portugal Journal's homepage in redalyc.org Non-profit academic project, developed under the open access initiative Nutr Hosp. 2017; 34(5):1205-1214 ISSN 0212-1611 - CODEN NUHOEQ S.V.R. 318 Nutrición Hospitalaria Revisión The nutritional limitations of plant-based beverages in infancy and childhood Limitaciones nutricionales de las bebidas vegetales en la lactancia y la infancia Isidro Vitoria Unit of Nutrition and Metabolopathies. Hospital Universitario y Politécnico La Fe. Valencia, Spain Abstract Breastfeeding, infant formula and cow’s milk are basic foods in infant nutrition. However, they are being increasingly replaced either totally or partially by plant-based beverages. The composition of 164 plant-based beverages available in Spain was reviewed based on the nutritional labeling of the package and the man- ufacturers’ webpages. This was compared to the composition of cow’s milk and infant formula. In addition, the nutritional disease associated with consumption of plant-based beverages in infants and children was reviewed by means of a literature search in Medline and Embase since 1990 based on the key words “plant-based beverages” or “rice beverages” or “almond beverages” or “soy beverages” and “infant” or “child”.
    [Show full text]
  • Genes Investigated
    BabyNEXTTM EXTENDED Investigated genes and associated diseases Gene Disease OMIM OMIM Condition RUSP gene Disease ABCC8 Familial hyperinsulinism 600509 256450 Metabolic disorder - ABCC8-related Inborn error of amino acid metabolism ABCD1 Adrenoleukodystrophy 300371 300100 Miscellaneous RUSP multisystem (C) * diseases ABCD4 Methylmalonic aciduria and 603214 614857 Metabolic disorder - homocystinuria, cblJ type Inborn error of amino acid metabolism ACAD8 Isobutyryl-CoA 604773 611283 Metabolic Disorder - RUSP dehydrogenase deficiency Inborn error of (S) ** organic acid metabolism ACAD9 acyl-CoA dehydrogenase-9 611103 611126 Metabolic Disorder - (ACAD9) deficiency Inborn error of fatty acid metabolism ACADM Acyl-CoA dehydrogenase, 607008 201450 Metabolic Disorder - RUSP medium chain, deficiency of Inborn error of fatty (C) acid metabolism ACADS Acyl-CoA dehydrogenase, 606885 201470 Metabolic Disorder - RUSP short-chain, deficiency of Inborn error of fatty (S) acid metabolism ACADSB 2-methylbutyrylglycinuria 600301 610006 Metabolic Disorder - RUSP Inborn error of (S) organic acid metabolism ACADVL very long-chain acyl-CoA 609575 201475 Metabolic Disorder - RUSP dehydrogenase deficiency Inborn error of fatty (C) acid metabolism ACAT1 Alpha-methylacetoacetic 607809 203750 Metabolic Disorder - RUSP aciduria Inborn error of (C) organic acid metabolism ACSF3 Combined malonic and 614245 614265 Metabolic Disorder - methylmalonic aciduria Inborn error of organic acid metabolism 1 ADA Severe combined 608958 102700 Primary RUSP immunodeficiency due
    [Show full text]
  • Inherited Metabolic Disorders)
    1 โรคพันธุกรรมเมตาบอลิก (inherited metabolic disorders) บทนํา โรคพันธุกรรมเมตาบอลิคนั้น มีผู้ประเมินไว้ว่ามีหลายร้อยโรคด้วยกัน และเป็นที่ยอมรับว่า อุบัติการของโรคกลุ่มนี้มักจะน้อยกว่าความเป็นจริง เนื่องจากการวินิจฉัยโรคทําได้ด้วยความ ยากลําบาก แพทย์ทั่วไปมักรู้จักค่อนข้างน้อย หรือให้การวินิจฉัยไม่ถูกต้อง ด้วยเหตุผลหลาย ประการ 1). การวินิจฉัยทําได้ค่อนข้างยาก เนื่องจากแต่ละโรคพบได้น้อยคือ จัดเป็น rare disease ทําให้แพทย์ไม่ค่อยนึกถึงเมื่อพบผู้ป่วย จนอาการค่อนข้างมาก หรือเมื่อได้แยกโรคที่พบได้บ่อย ออกไปแล้ว 2). การตรวจทางห้องปฎิบัติการโดยเฉพาะการตรวจเลือดและปัสสาวะเบื้องต้น มักไม่ ค่อยบอกโรคชัดเจน ยกเว้นส่งตรวจพิเศษบางอย่างเช่นการวิเคราะห์ plasma amino acid หรือ urine organic acid 3). ในทารกแรกเกิดซึ่งมีโอกาสพบโรคกลุ่มนี้ได้บ่อย มักจะมีการตอบสนองต่อ severe overwhelming illness อย่างมีขีดจํากัด หรือแสดงอาการอย่าง nonspecific เช่น poor feeding,lethargy เป็นต้น 4).กุมารแพทย์คิดถึงโรคกลุ่มนี้ในบางภาวะเท่านั้นเช่นภาวะปัญญาอ่อน หรือชักที่คุมได้ยากและมองข้ามอาการแสดงบางอย่างที่อาจเป็นเงื่อนงําสําคัญในการวินิจฉัยโรค โรคพันธุกรรมเมตาบอลิก ที่เรียกว่า inherited metabolic disorders หรือ inborn errors of metabolism (IBEM) เป็นโรคพันธุกรรมกลุ่มหนึ่งที่เกิดจากความผิดปกติของยีนเดี่ยว ที่มีความ ผิดปกติของการเรียงลําดับของเบสหรือสายDNA ก่อให้เกิดความผิดปกติของ enzymes, receptors, transport proteins, structural proteins, หรือส่วนประกอบอื่นของเซลล์แล้วส่งผลให้ เกิดความผิดปกติของขบวนการย่อยสลาย (catabolism) หรือขบวนการสังเคราะห์ (anabolism) สารอาหาร การเปลี่ยนแปลงที่ระดับ DNA ของโรคกลุ่มนี้อาจเกิดจากการกลายพันธุ์ของยีนที่สร้าง enzyme หรือยีนที่สร้างสารควบคุมหรือส่งเสริมการทํางานของ
    [Show full text]
  • Metabolomic Analysis Reveals That the Drosophila Gene Lysine Influences Diverse Aspects of Metabolism
    Genetics: Early Online, published on October 6, 2017 as 10.1534/genetics.117.300201 Metabolomic analysis reveals that the Drosophila gene lysine influences diverse aspects of metabolism Samantha L. St. Clair*‡, Hongde Li*‡, Usman Ashraf†, Jonathan A. Karty†, and Jason M. *§ Tennessen * Department of Biology, Indiana University, Bloomington, IN 47405, USA † Department of Chemistry, Indiana University, Bloomington, IN, 47405, USA. ‡ These authors contributed equally to this work. § Correspondence: [email protected] Keywords: Drosophila, metabolomics, lysine, LKRSDH, familial hyperlysinemia 1 Copyright 2017. ABSTRACT The fruit fly Drosophila melanogaster has emerged as a powerful model for investigating the molecular mechanisms that regulate animal metabolism. A major limitation of these studies, however, is that many metabolic assays are tedious, dedicated to analyzing a single molecule, and rely on indirect measurements. As a result, Drosophila geneticists commonly use candidate gene approaches, which, while important, bias studies towards known metabolic regulators. In an effort to expand the scope of Drosophila metabolic studies, we used the classic mutant lysine (lys) to demonstrate how a modern metabolomics approach can be used to conduct forward genetic studies. Using an inexpensive and well-established gas chromatography-mass spectrometry (GC-MS)-based method, we genetically mapped and molecularly characterized lys by using free lysine levels as a phenotypic readout. Our efforts revealed that lys encodes the Drosophila homolog of Lysine Ketoglutarate Reductase/Saccharopine Dehydrogenase (LKRSDH), which is required for the enzymatic degradation of lysine. Furthermore, this approach also allowed us to simultaneously survey a large swath of intermediate metabolism, thus demonstrating that Drosophila lysine catabolism is complex and capable of influencing seemingly unrelated metabolic pathways.
    [Show full text]
  • Amino Acid Disorders
    471 Review Article on Inborn Errors of Metabolism Page 1 of 10 Amino acid disorders Ermal Aliu1, Shibani Kanungo2, Georgianne L. Arnold1 1Children’s Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA; 2Western Michigan University Homer Stryker MD School of Medicine, Kalamazoo, MI, USA Contributions: (I) Conception and design: S Kanungo, GL Arnold; (II) Administrative support: S Kanungo; (III) Provision of study materials or patients: None; (IV) Collection and assembly of data: E Aliu, GL Arnold; (V) Data analysis and interpretation: None; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Correspondence to: Georgianne L. Arnold, MD. UPMC Children’s Hospital of Pittsburgh, 4401 Penn Avenue, Suite 1200, Pittsburgh, PA 15224, USA. Email: [email protected]. Abstract: Amino acids serve as key building blocks and as an energy source for cell repair, survival, regeneration and growth. Each amino acid has an amino group, a carboxylic acid, and a unique carbon structure. Human utilize 21 different amino acids; most of these can be synthesized endogenously, but 9 are “essential” in that they must be ingested in the diet. In addition to their role as building blocks of protein, amino acids are key energy source (ketogenic, glucogenic or both), are building blocks of Kreb’s (aka TCA) cycle intermediates and other metabolites, and recycled as needed. A metabolic defect in the metabolism of tyrosine (homogentisic acid oxidase deficiency) historically defined Archibald Garrod as key architect in linking biochemistry, genetics and medicine and creation of the term ‘Inborn Error of Metabolism’ (IEM). The key concept of a single gene defect leading to a single enzyme dysfunction, leading to “intoxication” with a precursor in the metabolic pathway was vital to linking genetics and metabolic disorders and developing screening and treatment approaches as described in other chapters in this issue.
    [Show full text]
  • Formula Name Category Description Qualifying
    Memorandum #17-079 TO: WIC Regional Directors WIC Local Agency Directors FROM: Amanda Hovis, Director Nutrition Education/Clinic Services Unit Nutrition Services Section DATE: August 4, 2017 SUBJECT: Revised Formula Approval Resources Posted The formula approval resources have been revised to reflect the recent clinic formula table changes and will be posted to the DSHS WIC website. You will be able view them at the following link under “Formula Approval Resources” once they are posted. http://www.dshs.texas.gov/wichd/nut/foods-nut.shtm The following documents have been revised for July, 2017. Presently, they are attached to this memo as PDF files. 1. Texas WIC Formulary 2. Formula Code List 3. Texas WIC Formula Maximum Quantity Table 4. Nutrition Assessment Requirements Guide If you have questions or require additional information, contact Pat Koym, Formula Specialist, at [email protected] or 512-341-4578. This institution is an equal opportunity provider TEXAS WIC FORMULARY AND MEDICAL REASONS FOR ISSUANCE JULY 2017 Formula Category Description Qualifying Conditions Staff Instructions - May issue for 1 cert Manufacturer Name period unless otherwise indicated Alfamino Infant Elemental 20 cal/oz when mixed 1 scoop to 1 oz 1) Malabsorption syndrome Formula history required. Nestle water; hypoallergenic amino acid 2) GI impairment When requested for food allergy - a failed trial of a protein based elemental. 43% of fat is MCT 3) GER/GERD hydrolysate (Extensive HA, Nutramigen, Alimentum, or oil; Similar to Elecare DHA/ARA, 4) Food allergies (cow's milk, soy or Pregestimil) is recommended before issuing unless medically Neocate DHA/ARA and PurAmino.
    [Show full text]